Skip to main content
SpringerLink
Log in

Mouse Models of Myeloproliferative Disease Associated with Mutant JAK2 Tyrosine Kinase: Insights into Pathophysiology and Therapy

  • Chapter
  • First Online:
Mouse Models of Human Blood Cancers

  • 606 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ayton PM, Cleary ML (2003) Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 17:2298–2307

    Article  PubMed  CAS  Google Scholar 

  • Barnes DJ, Schultheis B, Adedeji S, Melo JV (2005) Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 24:6432–6440

    PubMed  CAS  Google Scholar 

  • Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061

    PubMed  CAS  Google Scholar 

  • Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW (2006) Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 66:11156–11165

    Article  PubMed  CAS  Google Scholar 

  • Cools J, DeAngelo DJ, Gotlib J, Stover EH, Lagare RD, Cottes J, Kutok J, Clark J, Galinsky I, Griffin JD et al. (2003) A tyrosine kinase created by fusion of the PDGFA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201–1214

    Article  PubMed  CAS  Google Scholar 

  • Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824–830

    Article  PubMed  CAS  Google Scholar 

  • Daley GQ, Van Etten RA, Baltimore D (1991) Blast crisis in a murine model of chronic myelogenous leukemia. Proc Natl Acad Sci USA 88:11335–11338

    Article  PubMed  CAS  Google Scholar 

  • Dameshek W (1951) Some speculations on the myeloproliferative disorders. Blood 6:372–375

    PubMed  CAS  Google Scholar 

  • Dash AB, Williams IR, Kutok JL, Tomasson MH, Anastasiadou E, Lindahl K, Li S, Van Etten RA, Borrow J, Housman D et al. (2002) A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOX49. Proc Natl Acad Sci USA 99:7622–7627

    Article  PubMed  CAS  Google Scholar 

  • Deininger MW, Goldman JM, Lydon N, Melo JV (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691–3698

    PubMed  CAS  Google Scholar 

  • Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561–566

    Article  PubMed  CAS  Google Scholar 

  • Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92:1736–1744

    Article  PubMed  CAS  Google Scholar 

  • Gavrilescu LC, Van Etten RA (2008). Applications of murine retroviral bone marrow transplantation models for the study of human myeloproliferative disorders. In: Enna SJ, Williams M, Ferkany JW, Kenakin T, Moser P, Ruggeri B (eds) Current protocols in pharmacology, John Wiley & Sons, Inc., Pagosa Springs, CO

    Google Scholar 

  • Gishizky MI, Johnson-White J, Witte ON (1993) Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci USA 90:3755–3759

    Article  PubMed  CAS  Google Scholar 

  • Golub TR, Barker GF, Lovett M, Gilliland DG (1994) Fusion of the PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307–316

    Article  PubMed  CAS  Google Scholar 

  • Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R (2003) Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 100:7830–7835

    Article  PubMed  CAS  Google Scholar 

  • Hao SX, Ren R (2000) Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and enforced coexpression of ICSBP inhibits Bcr-Abl induced myeloproliferative disorder. Mol Cell Biol 20:1149–1161

    Article  PubMed  CAS  Google Scholar 

  • Heisterkamp N, Jenster G, Kioussis D, Pattengale PK, Groffen J (1991) Human bcr-abl gene has a lethal effect on embryogenesis. Transgenic Res 1:45–53

    Article  PubMed  CAS  Google Scholar 

  • Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, Van Etten RA, Li S (2004) Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 36:453–461

    Article  PubMed  CAS  Google Scholar 

  • Huettner CS, Zhang P, Van Etten RA, Tenen DG (2000) Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 24:57–60

    Article  PubMed  CAS  Google Scholar 

  • Ingley E, McCarthy DJ, Pore JR, Sarna MK, Adenan AS, Wright MJ, Erber W, Tilbrook PA, Klinken SP (2005) Lyn deficiency reduces GATA-1, EKLF and STAT5, and induces extramedullary stress erythropoiesis. Oncogene 24:336–343

    Article  PubMed  CAS  Google Scholar 

  • Jaiswal S, Traver D, Miyamoto T, Akashi K, Lagasse E, Weissman IL (2003) Expression of BCR/ABL and BCL2 in myeloid progenitors leads to myeloid leukemias. Proc Natl Acad Sci USA 100:10002–10007

    Article  PubMed  CAS  Google Scholar 

  • James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144–1148

    Article  PubMed  CAS  Google Scholar 

  • Jiang X, Stuible M, Chalandon Y, Li A, Chan WY, Eisterer W, Krystal G, Eaves A, Eaves C (2003) Evidence for a positive role of SHIP in BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia. Blood 102:2976–2984

    Article  PubMed  CAS  Google Scholar 

  • Jones AV, Cross NC (2004) Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci 61:2912–2923

    Article  PubMed  CAS  Google Scholar 

  • Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH et al. (2005a) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162–2168

    Article  CAS  Google Scholar 

  • Jones AV, Silver RT, Waghorn K, Curtis C, Kreil S, Zoi K, Hochhaus A, Oscier D, Metzgeroth G, Lengfelder E et al. (2005b) Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 107:3339–3341

    Article  Google Scholar 

  • Kelliher MA, McLaughlin J, Witte ON, Rosenberg N (1990) Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and bcr/abl. Proc Natl Acad Sci USA 87:6649–6653

    Article  PubMed  CAS  Google Scholar 

  • Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT (1997) Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 90:2057–2061

    PubMed  CAS  Google Scholar 

  • Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790

    Article  PubMed  CAS  Google Scholar 

  • Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, Skoda RC (2006) Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 108:1377–1380

    Article  PubMed  CAS  Google Scholar 

  • Krause DS, Van Etten RA (2004) Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model. Blood 104:4236–4244

    Article  PubMed  CAS  Google Scholar 

  • Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172–187

    Article  PubMed  CAS  Google Scholar 

  • Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108:1652–1660

    Article  PubMed  CAS  Google Scholar 

  • Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397

    Article  PubMed  CAS  Google Scholar 

  • Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA (1999) The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 189:1399–1412

    Article  PubMed  CAS  Google Scholar 

  • Macdonald D, Reiter A, Cross NCP (2002) The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 107:101–107

    Article  PubMed  CAS  Google Scholar 

  • Meng F, Lowell CA (1997) Lipopolysaccharide (LPS)-induced macrophage activation and signal transduction in the absence of Src-family kinases Hck, Fgr, and Lyn. J Exp Med 185:1661–1670

    Article  PubMed  CAS  Google Scholar 

  • Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A et al. (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379:645–648

    Article  PubMed  CAS  Google Scholar 

  • Million RP, Aster J, Gilliland DG, Van Etten RA (2002) The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood 99:4568–4577

    Article  PubMed  CAS  Google Scholar 

  • Moliterno AR, Hankins WD, Spivak JL (1998) Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 338:572–580

    Article  PubMed  CAS  Google Scholar 

  • Pardanani A (2008) JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22:23–30

    Google Scholar 

  • Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H et al. (2007) TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21:1658–1668

    Article  PubMed  CAS  Google Scholar 

  • Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ et al. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108:3472–3476

    Article  PubMed  CAS  Google Scholar 

  • Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, Colamonici OR, van Deursen JM et al. (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93:385–395

    Article  PubMed  CAS  Google Scholar 

  • Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, Pendergast AM, Bronson R, Aster JC, Scott ML, Baltimore D (1998) Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92:3780–3792

    PubMed  CAS  Google Scholar 

  • Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I et al. (2006) MPLW515L Is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270

    Article  PubMed  Google Scholar 

  • Prchal JF, Axelrad AA (1974) Letter: bone-marrow responses in polycythemia vera. N Engl J Med 290:1382

    PubMed  CAS  Google Scholar 

  • Richmond TD, Chohan M, Barber DL (2005) Turning cells red: signal transduction mediated by erythropoietin. Trends Biochem Sci 15:146–155

    CAS  Google Scholar 

  • Roumiantsev S, de Aos I, Varticovski L, Ilaria RL, Van Etten RA (2001) The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood 97:4–13

    Article  PubMed  CAS  Google Scholar 

  • Roumiantsev S, Krause DS, Neumann CA, Dimitri CA, Asiedu F, Cross NC, Van Etten RA (2004) Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 5:287–298

    Article  PubMed  CAS  Google Scholar 

  • Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S, Wooster R, Stratton MR, Futreal PA, Green AR (2005) The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 106:2920–2921

    Article  PubMed  CAS  Google Scholar 

  • Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN et al. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459–468

    Article  PubMed  CAS  Google Scholar 

  • Spivak JL (2002) Polycythemia vera: myths, mechanisms, and management. Blood 100:4272–4290

    Article  PubMed  CAS  Google Scholar 

  • Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood 106:1207–1209

    Article  PubMed  CAS  Google Scholar 

  • Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14–22

    Google Scholar 

  • Temerinac S, Klippel S, Strunck E, Roder S, Lubbert M, Lange W, Azemar M, Meinhardt G, Schaefer HE, Pahl HL (2000) Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 95:2569–2576

    PubMed  CAS  Google Scholar 

  • Tiedt R, Hao-Shen H, Looser R, Dirnhofer S, Schwaller J, Skoda RC (2008) Ratio of mutant JAK2-V617F to wild type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111:3931–3940

    Google Scholar 

  • Ugo V, Marzac C, Teyssandier I, Larbret F, Lecluse Y, Debili N, Vainchenker W, Casadevall N (2004) Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 32:179–187

    Article  PubMed  CAS  Google Scholar 

  • Van Etten RA (2001) Models of chronic myeloid leukemia. Curr Oncol Rep 3:228–237

    Article  PubMed  Google Scholar 

  • Van Etten RA (2002) Studying the pathogenesis of BCR-ABL + leukemia in mice. Oncogene 21:8643–8651

    Article  PubMed  Google Scholar 

  • Van Etten RA, Shannon KM (2004) Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 6:547–552

    Article  PubMed  Google Scholar 

  • Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292–2302

    Article  PubMed  CAS  Google Scholar 

  • Weinstein IB (2002) Addiction to oncogenes-the Achilles heal of cancer. Science 297:63–64

    Article  PubMed  CAS  Google Scholar 

  • Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG (2006) Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107:4274–4281

    Article  PubMed  CAS  Google Scholar 

  • Wolff NC, Ilaria RL Jr (2001) Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 98:2808–2816

    Article  PubMed  CAS  Google Scholar 

  • Xiao S, Nalabolu SR, Aster JC, Ma J, Abruzzo L, Jaffe ES, Stone R, Weissman SM, Hudson TJ, Fletcher JA (1998) FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nature Genet 18:84–87

    Article  PubMed  CAS  Google Scholar 

  • Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA (2006) Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F. PLoS ONE 1:e18

    Article  PubMed  Google Scholar 

  • Zhang X, Ren R (1998) Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 92:3829–3840

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Oncology Research Institute and Division of Hematology/Oncology, Tufts Medical Center, 800 Washington Street, 5609, Boston, MA 02111, USA

    Richard A. Van Etten

Authors
  1. Richard A. Van Etten
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2008 Springer Science+Business Media, LLC

    About this chapter

    Cite this chapter

    Van Etten, R.A. (2008). Mouse Models of Myeloproliferative Disease Associated with Mutant JAK2 Tyrosine Kinase: Insights into Pathophysiology and Therapy. In: Li, S. (eds) Mouse Models of Human Blood Cancers. Springer, New York, NY. https://doi.org/10.1007/978-0-387-69132-9_1

    Download citation

    Publish with us

    Policies and ethics

    Search

    Navigation